Ridgeback Biotherapeutics to Launch Two Trials of Its COVID-19 Antiviral

By Sam | June 22, 2020

Ridgeback Biotherapeutics in July will launch two phase 2 trials of its investigational antiviral EIDD-2801 as a potential COVID-19 treatment.
Source: Devices & Diagnostics Letter